Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 8Recruiting 6Terminated 1Suspended 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

Specimen Handling 29Magnetic Resonance Spectroscopy 20Biopsy 19Cyclophosphamide 8venetoclax 5Bevacizumab 5Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Cetuximab 4Azacitidine 4fludarabine phosphate 3fludarabine 3decitabine and cedazuridine drug combination 3X-Rays 3Radiosurgery 3Radiation 3Prednisone 3Doxorubicin 3zanubrutinib 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2deltacortene 2Tacrolimus 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × ipatasertib × 90 days × Clear all
NCT05554380 2026-05-22

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡